Page 913 - Adams and Stashak's Lameness in Horses, 7th Edition

Principles of Therapy for Lameness 879

19. Fortier LA, Motta T, Greenwald RA, et al. Synoviocytes are more injury. Am J Physiol Renal Physiol 2004;287:F760–F766. doi:10.
sensitive than cartilage to the effects of minocycline and doxycy- 42. Knych HK, Stanley SD, Seminoff KN, et al. Pharmacokinetics of
1152/ajprenal.00050.
cline on IL‐1alpha and MMP‐13‐induced catabolic gene responses.
VetBooks.ir 20. Francis DJ, Forrest MJ, Brooks PM, et al. Retardation of articular methocarbamol and phenylbutazone in exercised Thoroughbred
J Orthop Res 2010;28:522–528. doi:10.1002/jor.21006.
horses. J Vet Pharmacol Ther 2016;39:469–477. doi:10.1111/
cartilage degradation by glycosaminoglycan polysulfate, pentosan
jvp.12298.
polysulfate, and DH‐40J in the rat air pouch model. Arthritis
Rheum 1989;32:608–616. 43. Kollias‐Baker C. Therapeutics of musculoskeletal disease in the
horse. Vet Clin North Am Equine Pract 1999;15:589–602.
21. Frean SP, Cambridge H, Lees P. Effects of anti‐arthritic drugs on 44. Laurent UB, Fraser JR, Engström‐Laurent A, et al. Catabolism
proteoglycan synthesis by equine cartilage. J Vet Pharmacol Ther of hyaluronan in the knee joint of the rabbit. Matrix 1992;12:
2002;25:289–298. 130–136.
22. Frevel M, Knight BL, Kolb DS, et al. Clodronate disodium for treat- 45. Leite LM, Carvalho AG, Ferreira PL, et al. Anti‐inflammatory
ment of clinical signs of navicular disease ‐ a double‐blinded pla- properties of doxycycline and minocycline in experimental models:
cebo‐controlled clinical trial. Pferdeheilkunde 2017;33:271–279. an in vivo and in vitro comparative study. Inflammopharmacology
23. Frisbie DD. Joint Disease in the Horse, 2nd ed. McIlwraith CW, 2011;19:99–110. doi:10.1007/s10787‐011‐0077‐5.
Frisbie DD, Kawcak CE, et al., eds. Elsevier, 2016;215–219. 46. Li C, Mori S, Li J, et al. Long‐term effect of incadronate disodium
24. Frisbie DD, Kawcak CE, McIlwraith CW. Evaluation of the effect (YM‐175) on fracture healing of femoral shaft in growing rats. J
of extracorporeal shock wave treatment on experimentally Bone Miner Res 2001;16:429–436. doi:10.1359/jbmr.2001.
induced osteoarthritis in middle carpal joints of horses. Am J Vet 16.3.429.
Res 2009;70:449–454. doi:10.2460/ajvr.70.4.449. 47. Maher MC, Schnabel LV, Cross JA, et al. Plasma and synovial
25. Frisbie DD, McIlwraith CW, Kawcak CE, et al. Efficacy of intra- fluid concentration of doxycycline following low‐dose, low‐fre-
venous administration of hyaluronan, sodium chondroitin sulfate, quency administration, and resultant inhibition of matrix metal-
and N‐acetyl‐d‐glucosamine for prevention or treatment of osteo- loproteinase‐13 from interleukin‐stimulated equine synoviocytes.
arthritis in horses. Am J Vet Res 2016;77:1064–1070. doi:10.2460/ Equine Vet J 2014;46:198–202. doi:10.1111/evj.12139.
ajvr.77.10.1064. 48. McDonald MM, Dulai S, Godfrey C, et al. Bolus or weekly zole-
26. Fubini SL, Boatwright CE, Todhunter RJ, et al. Effect of intramus- dronic acid administration does not delay endochondral fracture
cularly administered polysulfated glycosaminoglycan on articular repair but weekly dosing enhances delays in hard callus remode-
cartilage from equine joints injected with methylprednisolone ling. Bone 2008;43:653–662. doi:10.1016/j.bone.2008.05.019.
acetate. Am J Vet Res 1993;54:1359–1365. 49. McIlwraith CW. Joint Disease in the Horse, 2nd ed. McIlwraith
27. Fuller CJ, Ghosh P, Barr AR. Plasma and synovial fluid concentra- CW, Frisbie DD, Kawcak CE, et al., eds. Elsevier, 2016;224–228.
tions of calcium pentosan polysulphate achieved in the horse fol- 50. McIlwraith CW, Frisbie DD, Kawcak CE. Evaluation of intramus-
lowing intramuscular injection. Equine Vet J 2002;34:61–64. cularly administered sodium pentosan polysulfate for treatment
28. Gee NS, Brown JP, Dissanayake VU, et al. The novel anticonvul- of experimentally induced osteoarthritis in horses. Am J Vet Res
sant drug, gabapentin (Neurontin), binds to the alpha2delta subu- 2012;73:628–633. doi:10.2460/ajvr.73.5.628.
nit of a calcium channel. J Biol Chem 1996;271:5768–5776. 51. Nethery A, Giles I, Jenkins K, et al. The chondroprotective drugs,
29. Ghosh P. The pathobiology of osteoarthritis and the rationale for Arteparon and sodium pentosan polysulphate, increase colla-
the use of pentosan polysulfate for its treatment. Semin Arthritis genase activity and inhibit stromelysin activity in vitro. Biochem
Rheum 1999;28:211–267. Pharmacol 1992;44:1549–1553.
30. Ghosh P, Guidolin D. Potential mechanism of action of intra‐artic- 52. Nieman GF, Zerler BR. A role for the anti‐inflammatory proper-
ular hyaluronan therapy in osteoarthritis: are the effects molecu- ties of tetracyclines in the prevention of acute lung injury. Curr
lar weight dependent? Semin Arthritis Rheum 2002;32:10–37. Med Chem 2001;8:317–325.
31. Ghosh P, Smith M. Osteoarthritis, genetic and molecular mecha- 53. Nishikawa H, Mori I, Umemoto J. Influences of sulfated glycosa-
nisms. Biogerontology 2002;3:85–88. minoglycans on biosynthesis of hyaluronic acid in rabbit knee
32. Goodrich LR, Nixon AJ. Medical treatment of osteoarthritis in synovial membrane. Arch Biochem Biophys 1985;240:146–153.
the horse ‐ a review. Vet J 2006;171:51–69. doi:10.1016/j.tvjl. 54. Peter CP, et al. Effect of alendronate on fracture healing and bone
2004.07.008. remodeling in dogs. J Orthop Res 1996;14:74–79. doi:10.1002/
33. Goodship AE, Walker PC, McNally D, et al. Use of a bisphospho- jor.1100140113.
nate (pamidronate) to modulate fracture repair in ovine bone. 55. Pisko EJ, Turner RA, Soderstrom LP, et al. Inhibition of neutrophil
Ann Oncol 1994;5(Suppl 7):S53–S55. phagocytosis and enzyme release by hyaluronic acid. Clin Exp
34. Gustafson SB, McIlwraith CW, Jones RL. Comparison of the Rheumatol 1983;1:41–44.
effect of polysulfated glycosaminoglycan, corticosteroids, and 56. Plosker GL, Goa KL. Clodronate. A review of its pharmacological
sodium hyaluronate in the potentiation of a subinfective dose of properties and therapeutic efficacy in resorptive bone disease.
Staphylococcus aureus in the midcarpal joint of horses. Am J Vet Drugs 1994;47:945–982.
Res 1989;50:2014–2017. 57. Popot MA, Bonnaire Y, Guechot J, et al. Hyaluronan in horses:
35. Hamm D, Jones EW. Intra‐articular (IA) and intramuscular (IM) physiological production rate, plasma and synovial fluid concen-
treatment of noninfectious equine arthritis (DJD) with polysul- trations in control conditions and following sodium hyaluronate
fated glycosaminoglycan (PSGAG). J Equine Vet Sci 1988;8: administration. Equine Vet J 2004;36:482–487.
456–459. 58. Raatikainen T, Vaananen K, Tamelander G. Effect of glycosamino-
36. Haugland LM, Collier MA, Default LE, et al. 3H‐PSGAG concen- glycan polysulfate on chondromalacia patellae. A placebo‐con-
tration in the synovial fluid of the equine antebrachiocarpal, met- trolled 1‐year study. Acta Orthop Scand 1990;61:443–448.
acarpophalangeal, coronopedal and tibiotarsal joints following a 59. Readford PK, Lester GD, Secombe CJ. Temporohyoid osteoar-
500 MG i. J Equine Vet Sci 1995;15:274–278. doi:10.1016/ thropathy in two young horses. Aust Vet J 2013;91:209–212.
S0737‐0806(07)80497‐7. doi:10.1111/avj.12039.
37. Hector RC, Mama KR. Equine Internal Medicine, 4th ed. Reed 60. Sadowski T, Steinmeyer J. Effects of tetracyclines on the produc-
SM, Bayly WM, Sellon DC, eds. Elsevier, 2018;138–157. tion of matrix metalloproteinases and plasminogen activators as
38. Helweg MJ, Metzemacher S, Schulze T, et al. Bone oedema like well as of their natural inhibitors, tissue inhibitor of metallopro-
lesion of the second phalanx causing a non‐weight bearing lame- teinases‐1 and plasminogen activator inhibitor‐1. Inflamm Res
ness in a 4 years old Trakehnen mare. Pferdeheilkunde 2014;30: 2001;50:175–182. doi:10.1007/s000110050742.
165–175. 61. Salazar V, Dewey CW, Schwark W, et al. Pharmacokinetics of sin-
39. Jones IL, Sandstrom T. Enhanced breakdown of bovine articular gle‐dose oral pregabalin administration in normal dogs. Vet Anaesth
cartilage proteoglycans by conditioned synovial medium in vitro. Analg 2009;36:574–580. doi:10.1111/j.1467‐2995.2009.00486.x.
The effect of glycosaminoglycan polysulfate. Arzneimittelforschung 62. Schnabel LV, Papich MG, Watts AE, et al. Orally administered
1985;35:141–144. doxycycline accumulates in synovial fluid compared to
40. Kawcak CE, Frisbie DD, Trotter GW, et al. Effects of intravenous plasma. Equine Vet J 2010;42:208–212. doi:10.2746/042516
administration of sodium hyaluronate on carpal joints in exercis- 409X478514.
ing horses after arthroscopic surgery and osteochondral fragmen- 63. Shima K, Nemoto W, Tsuchiya M, et al. The bisphosphonates clo-
tation. Am J Vet Res 1997;58:1132–1140. dronate and etidronate exert analgesic effects by acting on gluta-
41. Kelly KJ, Sutton TA, Weathered N, et al. Minocycline inhibits mate‐ and/or ATP‐related pain transmission pathways. Biol Pharm
apoptosis and inflammation in a rat model of ischemic renal Bull 2016;39:770–777. doi:10.1248/bpb.b15‐00882.